Complementary Roles for Tissue- and Blood-Based Comprehensive Genomic Profiling for Detection of Actionable Driver Alterations in Advanced NSCLC

被引：17
作者：
Schwartzberg, Lee S. [1 ]
Li, Gerald [2 ]
Tolba, Khaled [2 ]
Bourla, Ariel B. [3 ]
Schulze, Katja [4 ]
Gadgil, Rujuta [5 ]
Fine, Alexander [6 ]
Lofgren, Katherine T. [7 ]
Graf, Ryon P. [2 ]
Oxnard, Geoffrey R. [2 ]
Daniel, Davey [8 ,9 ]
机构：
[1] West Canc Ctr, Germantown, TN USA
[2] Fdn Med, Clin Dev, Cambridge, MA USA
[3] Flatiron Hlth, New York, NY USA
[4] Genentech Inc, Oncol Biomarker Dev & Med Affairs, South San Francisco, CA USA
[5] Fdn Med, Clin Operat, Cambridge, MA USA
[6] Fdn Med, Canc Genom Res, Cambridge, MA USA
[7] Fdn Med, Decis Sci, Cambridge, MA USA
[8] Tennessee Oncol, Med Oncol, Chattanooga, TN USA
[9] Tennessee Oncol, 605 Glenwood Dr,Suite 200, Chattanooga, TN 37404 USA
来源：
JTO CLINICAL AND RESEARCH REPORTS | 2022年 / 3卷 / 09期
关键词：
Comprehensive genomic profiling; Liquid biopsy; Biomarkers; Tissue-based testing; NSCLC; LUNG-CANCER; DNA;
D O I：
10.1016/j.jtocrr.2022.100386
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Introduction: Whereas tumor biopsy is the reference standard for genomic profiling of advanced NSCLC, there are now multiple assays approved by the Food and Drug Administration for liquid biopsy testing of circulating tumor DNA. Here, we study the incremental value that liquid biopsy comprehensive genomic profiling (CGP) adds to tissue molecular testing.Methods: Patients with metastatic NSCLC were enrolled in a prospective diagnostic study to receive circulating tumor DNA CGP; tissue CGP was optional in addition to their standard tissue testing. Focusing on nine genes listed per the National Comprehensive Cancer Network (NCCN) guidelines, liquid CGP was compared with available tissue testing results across three subcohorts: tissue CGP, standard-of-care testing of up to five biomarkers, or no tissue testing.Results: A total of 515 patients with advanced nonsquamous NSCLC received liquid CGP. Among 131 with tissue CGP results, NCCN biomarkers were detected in 86 (66%) with tissue CGP and 56 (43%) with liquid CGP (p < 0.001). Adding liquid CGP to tissue CGP detected no additional patients with NCCN biomarkers, whereas tissue CGP detected NCCN biomarkers in 30 patients (23%) missed by liquid CGP. Studying 264 patients receiving tissue testing of up to five genes, 102 (39%) had NCCN biomarkers detected in tissue, with an additional 48 (18%) detected using liquid CGP, including 18 with RET, MET, or ERBB2 drivers not studied in tissue.Conclusions: For the detection of patients with advanced nonsquamous NSCLC harboring 9 NCCN biomarkers, liquid CGP increases detection in patients with limited tissue results, but does not increase detection in patients with tissue CGP results available. In contrast, tissue CGP can add meaningfully to liquid CGP for detection of NCCN biomarkers and should be considered as a follow-up when an oncogenic driver is not identified by liquid biopsy.(c) 2022 The Authors. Published by Elsevier Inc. on behalf of the International Association for the Study of Lung Cancer.
引用
收藏
页数：10
相关论文
共 28 条
  • [1] Strategies for the successful implementation of plasma-based NSCLC genotyping in clinical practice
    Aggarwal, Charu
    Rolfo, Christian D.
    Oxnard, Geoffrey R.
    Gray, Jhanelle E.
    Sholl, Lynette M.
    Gandara, David R.
    [J]. NATURE REVIEWS CLINICAL ONCOLOGY, 2021, 18 (01) : 56 - 62
  • [2] Clinical Implications of Plasma-Based Genotyping With the Delivery of Personalized Therapy in Metastatic Non-Small Cell Lung Cancer
    Aggarwal, Charu
    Thompson, Jeffrey C.
    Black, Taylor A.
    Katz, Sharyn I.
    Fan, Ryan
    Yee, Stephanie S.
    Chien, Austin L.
    Evans, Tracey L.
    Bauml, Joshua M.
    Alley, Evan W.
    Ciunci, Christine A.
    Berman, Abigail T.
    Cohen, Roger B.
    Lieberman, David B.
    Majmundar, Krishna S.
    Savitch, Samantha L.
    Morrissette, Jennifer J. D.
    Hwang, Wei-Ting
    Elenitoba-Johnson, Kojo S. J.
    Langer, Corey J.
    Carpenter, Erica L.
    [J]. JAMA ONCOLOGY, 2019, 5 (02) : 173 - 180
  • [3] Enabling Precision Oncology Through Precision Diagnostics
    Brown, Noah A.
    Elenitoba-Johnson, Kojo S. J.
    [J]. ANNUAL REVIEW OF PATHOLOGY: MECHANISMS OF DISEASE, VOL 15, 2020, 2020, 15 : 97 - 121
  • [4] Plasma cfDNA Genotyping in Hospitalized Patients With Suspected Metastatic NSCLC
    Cheng, Michael L.
    Milan, Marina S. D.
    Tamen, Rubii M.
    Bertram, Arrien A.
    Michael, Kesi S.
    Ricciuti, Biagio
    Kehl, Kenneth L.
    Awad, Mark M.
    Sholl, Lynette M.
    Paweletz, Cloud P.
    Janne, Pasi A.
    [J]. JCO PRECISION ONCOLOGY, 2021, 5 : 726 - 732
  • [5] Tumor fraction in cell-free DNA as a biomarker in prostate cancer
    Choudhury, Atish D.
    Werner, Lillian
    Francini, Edoardo
    Wei, Xiao X.
    Ha, Gavin
    Freeman, Samuel S.
    Rhoades, Justin
    Reed, Sarah C.
    Gydush, Gregory
    Rotem, Denisse
    Lo, Christopher
    Taplin, Mary-Ellen
    Harshman, Lauren C.
    Zhang, Zhenwei
    O'Connor, Edward P.
    Stover, Daniel G.
    Parsons, Heather A.
    Getz, Gad
    Meyerson, Matthew
    Love, J. Christopher
    Hahn, William C.
    Adalsteinsson, Viktor A.
    [J]. JCI INSIGHT, 2018, 3 (21):
  • [6] Analytical Validation of a Hybrid Capture-Based Next-Generation Sequencing Clinical Assay for Genomic Profiling of Cell-Free Circulating Tumor DNA
    Clark, Travis A.
    Chung, Jon H.
    Kennedy, Mark
    Hughes, Jason D.
    Chennagiri, Niru
    Lieber, Daniel S.
    Fendler, Bernard
    Young, Lauren
    Zhao, Mandy
    Coyne, Michael
    Breese, Virginia
    Young, Geneva
    Donahue, Amy
    Pavlick, Dean
    Tsiros, Alyssa
    Brennan, Timothy
    Zhong, Shan
    Mughal, Tariq
    Bailey, Mark
    He, Jie
    Roels, Steven
    Frampton, Garrett M.
    Spoerke, Jill M.
    Gendreau, Steven
    Lackner, Mark
    Schleifman, Erica
    Peters, Eric
    Ross, Jeffrey S.
    Ali, Siraj M.
    Miller, Vincent A.
    Gregg, Jeffrey P.
    Stephens, Philip J.
    Welsh, Allison
    Otto, Geoff A.
    Lipson, Doron
    [J]. JOURNAL OF MOLECULAR DIAGNOSTICS, 2018, 20 (05) : 686 - 702
  • [7] Non-Small Cell Lung Cancer, Version 2.2021 Featured Updates to the NCCN Guidelines
    Ettinger, David S.
    Wood, Douglas E.
    Aisner, Dara L.
    Akerley, Wallace
    Bauman, Jessica R.
    Bharat, Ankit
    Bruno, Debora S.
    Chang, Joe Y.
    Chirieac, Lucian R.
    D'Amico, Thomas A.
    Dilling, Thomas J.
    Dowell, Jonathan
    Gettinger, Scott
    Gubens, Matthew A.
    Hegde, Aparna
    Hennon, Mark
    Lackner, Rudy P.
    Lanuti, Michael
    Leal, Ticiana A.
    Lin, Jules
    Loo, Billy W., Jr.
    Lovly, Christine M.
    Martins, Renato G.
    Massarelli, Erminia
    Morgensztern, Daniel
    Ng, Thomas
    Otterson, Gregory A.
    Patel, Sandip P.
    Riely, Gregory J.
    Schild, Steven E.
    Shapiro, Theresa A.
    Singh, Aditi P.
    Stevenson, James
    Tam, Alda
    Yanagawa, Jane
    Yang, Stephen C.
    Gregory, Kristina M.
    Hughes, Miranda
    [J]. JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 2021, 19 (03): : 254 - 266
  • [8] Food and Drug Administration, FoundationOne Liquid CDx Technical Information.
  • [9] Food and Drug Administration, Guardant360 CDx Technical Information.
  • [10] Immunotherapy in EGFR-Mutant and ALK-Positive Lung Cancer Implications for Oncogene-Driven Lung Cancer
    Gavralidis, Alexander
    Gainor, Justin F.
    [J]. CANCER JOURNAL, 2020, 26 (06) : 517 - 524
123